News | Heart Valve Technology | May 14, 2018

3-D Printed Models to Guide TAVR Improve Outcomes

Results presented at SCAI 2018 show novel technology could reduce risks paravalvular leaks

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict paravalvular leak (PVL) in patients undergoing transcatheter aortic valve replacement (TAVR). A common risk of TAVR is an ill-fitting valve which can lead to PVL. To address this risk, the study used 3-D printing technology to help confirm and detect the location of the leak. The retrospective study was presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions.

More than 5 million Americans are diagnosed with heart valve disease each year.[1] TAVR is a procedure used for intermediate, high-risk, and inoperable patients with severe narrowing of the aortic valve where a prosthetic valve is implanted and the damaged valve is replaced. Patients who undergo TAVR, which is a less invasive procedure to replace the heart’s aortic valve, can experience paravalvular leak around the new valve which can lead to higher mortality rates. Therefore, clinicians are exploring ways to find and prevent these leaks from happening. 3D printing has become more popular within the medical space as it has been discovered to be a vital tool to prevent, fix and foresee procedural errors.

In the study, six patients undergoing TAVR for severe, calcific aortic stenosis and at risk for paravalvular leak had pre-procedure computed tomography (CT) images analyzed and segmented for printing of 3D models. The CT scans allowed researchers to see a 360-degree view of the location of the calcium build up while the 3D models allowed researchers to further evaluate the ill-fitting valves. The 3D aortic root models were then implanted with the valve to determine if the size was correct, ultimately revealing where the calcium composites would be. The 3D models were scanned, evaluated for final analysis and then compared to in-vivo implanted TAVR echocardiograms.

Every leak seen on the 3D models were confirmed on the CT digital scans. The 3D models allowed researchers to use prototypes to personalize valve placement, size and location to stop leaks and lower calcium build up.

“We are very encouraged to see such positive outcomes for the feasibility of 3D printing in patients with heart valve disease. These patients are at a high risk of developing a leak after TAVR, and anything we can do to identify and prevent these leaks from happening is certainly helpful,” said lead author Sergey Gurevich, M.D., and cardiovascular fellow at the University of Minnesota in Minneapolis, Minn. “Like any other new technology, as 3D printing evolves, we hope to see an increase in accessibility and opportunity for the use of this technology to help improve patient care.”

The authors call for a functional study to help determine the exact size of the leak. The authors of this study are working with computational fluid dynamics to optimize calculations.

Watch the VIDEO "Applications in Cardiology for 3-D Printing and Computer Aided Design" — interview with Dee Dee Wang, M.D., Director, Structural Heart Imaging at Henry Ford Hospital, Detroit.
 

Complete listing of SCAI 2018 late-breaking trials with links to articles.

Reference: 

1. American Heart Association. Under-recognized heart valve disease kills estimated 25,000 each year. https://news.heart.org/under-recognized-heart-valve-disease-kills-estimated-25000-each-year/. Accessed April 20, 2018.

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...